ENXTAM:PHARMBiotechs
A Look At Pharming Group (ENXTAM:PHARM) Valuation After The FDA Complete Response Letter For Joenja
Pharming Group (ENXTAM:PHARM) is back in focus after the U.S. FDA issued a Complete Response Letter for Joenja in children aged 4 to 11 with APDS, highlighting dosing and data requirements.
See our latest analysis for Pharming Group.
The FDA setback has been followed by a sharp 18.26% 7 day share price return decline. However, the 90 day share price return of 32.15% and 1 year total shareholder return of 75.94% suggest momentum has recently been building rather than fading.
If this kind of...